Europe In-Vitro Colorectal Cancer Screening Tests Market Report and Forecast 2025-2034

Europe In-Vitro Colorectal Cancer Screening Tests Market Outlook

The global in-vitro colorectal cancer screening tests market size was valued at USD 920.4 million in 2024, with Europe holding a significant market share. The market is driven by the rising prevalence of colorectal cancer across the region. It is expected to grow at a CAGR of 5.53% during the forecast period of 2025-2034, with the values likely to attain USD 1492.8 million by 2034.

Key Takeaways

• According to the World Health Organization, the burden of colorectal cancer is expected to rise to about 3.2 million new cases per year and nearly 1.6 million deaths per year by 2024. The highest mortality rates have been witnessed in Eastern Europe.

• Rising research activities are creating opportunities for Europe in-vitro colorectal cancer screening tests market growth. In February 2024, researchers at the Netherlands Cancer Institute, Amsterdam UMC, and Erasmus MC developed a new test called multitargetFIT-test (mtFIT), that measures hemoglobin with two additional proteins during the detection of pre-cursors of colorectal cancer.

• The market is expected to be driven by clinical-stage diagnostics companies understanding the need to explore their screening technologies to detect colorectal cancer, brain cancer, and lung cancer. Dxcover Limited announced initiating three clinical trials to measure the efficacy of their liquid biopsy technology in the mentioned conditions.

Europe In-Vitro Colorectal Cancer Screening Tests Market Analysis

Colorectal cancer is the third most common cancer across the globe. It claims nearly 10% of all cancer cases and is the second leading cause of cancer-related deaths worldwide. According to the World Health Organization, in 2020, more than 1.9 million new cases of colorectal cancer were recorded globally. Europe, Australia, and New Zealand experienced the highest incidence rates, and the mortality rates were highest in Eastern Europe. It is expected that the burden of colorectal cancer will increase to 3.2 million new cases per year (an increase of 63%) by 2040, and 1.6 million deaths per year (an increase of 73%).

Europe in-vitro colorectal cancer screening tests market share is expected to be elevate with increasing strategic moves of market players. Considering the urgency of diagnosing colorectal cancer in its early stages with accuracy, there have been dedicated efforts to develop effective products. On January 9, 2024, a clinical-stage diagnostics company Dxcover Limited, pioneering in multi-omic spectral analysis (MOSA) for the early detection of multiple cancers, announced the initiation of three pivotal clinical trials, measuring the efficacy of the company’s liquid biopsy technology for the detection of brain, colorectal, and lung cancer. Their CREATE2 trial is focused on evaluating the diagnostic accuracy for colorectal cancer and high-risk adenoma in patients who have been going through colonoscopy. With colorectal cancer already difficult to diagnose in early detection screenings, diagnosis at these stages will enable positive patient outcomes.

Europe in-vitro colorectal cancer screening tests market growth is anticipated to be positively impacted by the researchers innovating new testing methods for the detection of precursors of colorectal cancer. For instance, in February 2024, researchers at the Netherlands Cancer Institute, Amsterdam UMC, and Erasmus MC developed a new test, titled multitargetFIT-test (mtFIT). With the existing FIT test, the patient’s stool is analysed for hemoglobin, however mtFIT measures hemoglobin and two additional proteins. mtFIT is targeted to detect cancer precursors more effectively. Notable outcomes have also been registered in a large prospective study, in which mtFIT effectively detected cancer precursors in comparison to the current FIT. Based on the diagnostic test guidelines in Europe, the next step is to produce the mtFIT test on a larger industrial scale. This is because the test can be included in existing FIT-based screening programs, as the screening logistics requirements are similar. To facilitate the availability of the test for CRC screening participants in the Netherlands and other places, a company called CRCbioscreen has also been established.

Europe In-Vitro Colorectal Cancer Screening Tests Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Europe In-vitro Colorectal Cancer Screening Tests Market: Competitor Landscape

The key features of the market report include funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Epigenomics AG

• NOVIGENIX SA

• Merck KGaA

• Abbott

• Siemens Healthineers AG

• Sysmex Corporation

• Qiagen NV

• F. Hoffmann-La Roche Ltd

• Eiken Chemical Co., Ltd.

• Beckman Coulter, Inc.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

Europe In-Vitro Colorectal Cancer Screening Tests Market Report Snapshots

Europe In-Vitro Colorectal Cancer Screening Tests Market Size

Europe In-Vitro Colorectal Cancer Screening Tests Market Analysis

Europe In-Vitro Colorectal Cancer Screening Tests Companies